Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells-Reference-Cited by-同舟云学术

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Published:2021-01-08 Issue:5 Volume:11 Page:1100-1117
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Dovedi Simon J.,Elder Matthew J.,Yang Chunning,Sitnikova Suzanne I.,Irving Lorraine^ORCID,Hansen Anna,Hair James,Jones Des C.,Hasani Sumati^ORCID,Wang Bo,Im Seock-Ah^ORCID,Tran Ben,Subramaniam Deepa S.,Gainer Shelby D.,Vashisht Kapil,Lewis Arthur,Jin Xiaofang,Kentner Stacy,Mulgrew Kathy^ORCID,Wang Yaya,Overstreet Michael G.^ORCID,Dodgson James,Wu Yanli,Palazon Asis^ORCID,Morrow Michelle,Rainey Godfrey J.^ORCID,Browne Gareth J.,Neal Frances,Murray Thomas V.,Toloczko Aleksandra D.,Dall'Acqua William,Achour Ikbel^ORCID,Freeman Daniel J.,Wilkinson Robert W.,Mazor Yariv

Funder

AstraZeneca

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

2. A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC;International Immunopharmacology;2024-09

3. IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release;mAbs;2024-08-28

4. Developability considerations for bispecific and multispecific antibodies;mAbs;2024-08-27

5. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors;Molecular Diagnosis & Therapy;2024-08-22